{"pub": "afr", "url": "https://afr.com/markets/equity-markets/asx-slides-to-worst-weekly-drop-in-almost-a-year-20191004-p52xkc", "downloaded_at": "2019-10-05 06:14:51.286209+00:00", "title": "ASX slides to worst weekly drop in almost a year", "language": "en", "text": "\"In Australia there are a couple of levers being pulled. Rates are being cut and the pressure on fiscal stimulus to step up will increase,\" Mr Wong said.\n\nA lower cash rate increases margin pressure for the banks, however. \"Rate cuts are probably negative for the banks overall,\" Mr Wong said. \"They are not able to pass on rate cuts in full.\"\n\nCommonwealth Bank shares fell 4.9 per cent to $77.59. Regulators charged the bank's life insurance arm, CommInsure, with 87 breaches of anti-hawking legislation on Friday.\n\nNational Australia Bank dropped 6.6 per cent to $27.85. This week the bank said it would set aside an extra $832 million to refund ripped-off financial advice customers, sending the total cost to the bank of the fees-for-no-service scandal rocketing past $2 billion.\n\nWestpac shares fell 5 per cent to $28.42 and ANZ shares dropped 5.3 per cent to $27.17 over the week.\n\nBut Mr Wong was not negative on the sector. \"I'm not a bear,\" he said. \"They maintain a strong position and some degree of pricing power.\"\n\nSpeculation has risen that the banks will have to raise capital as margin pressure intensifies. \"I'm trying to work out if the prospects of capital raising are negative,\" he said. In the past \"when banks have raised capital, investors have made money\".\n\nAdvertisement\n\nAway from the banks, Mr Wong said he was looking for other companies with pricing power in tough times. He liked blood products group CSL.\n\nCSL shares jumped 3.2 per cent to $236.34 on Friday for a 0.9 per cent gain over the week, with Morgan Stanley analysts upgrading the firm to overweight from neutral and lifting CSL's price target to $251 a share.\n\nThe healthcare firm's earnings for fiscal 2020 could exceed expectations, the broker said, as tight immunoglobulin markets were expected to absorb higher supply\n\nMayne Pharma Group rallied 16 per cent to 58\u00a2, with investors responding favourably to the firm's 20-year oral contraceptive supply and licence deal with US pharmaceutical Mithra Pharmaceuticals.\n\nMacquarie analysts upgraded Mayne to neutral from underperform and lifted their price targe to 66\u00a2 from 51\u00a2 a day after the deal was announced. \"We see the agreement as providing an opportunity for both growth and diversification of earnings over the medium to longer term,\" they said.\n\nHealthcare was the only sector to record a gain over the week, rising 0.3 per cent.\n\nNufarm was another weekly standout, rallying 45.5 per cent to $6.49 in the week after it told shareholders it would cut ties with supply chains in China while offloading its South American business to Sumitomo for $1.18 billion.\n\nGold miner Northern Star rallied 6.5 per cent to $11.70, part of a broader rally for the gold mining sector as gold prices soared on safe-haven buying. Gold climbed 2.5 per cent in October and has been trading back above $US1500 an ounce.\n\nLithium miners were some of the worst weekly performers, as Pilbara Minerals fell 10.8 per cent to 29\u00a2 and Galaxy Resources dropped 13 per cent to 94\u00a2.", "description": "Just about every sector of the market fell over the week, with banks performing particularly poorly.", "authors": [], "top_image": "https://static.ffx.io/images/$zoom_0.5298%2C$multiply_0.7554%2C$ratio_1.777778%2C$width_1059%2C$x_0%2C$y_0/t_crop_custom/e_sharpen:25%2Cq_85%2Cf_auto/cbc410c6f3514a13c435121d54fdb4adcdfd2416", "published_at": "2019-10-04"}